Literature DB >> 24699042

The characteristics and prognostic analysis in 213 myeloid malignancy patients with del(20q): a report of a single-center case series.

Jinlan Pan1, Chunxiao Wu1, Yongquan Xue2, Huiying Qiu1, Suning Chen1, Jun Zhang1, Shuxiao Bai1, Yafang Wu1, Yong Wang1, Juan Shen1, Yanlei Gong1.   

Abstract

The clinical and hematological characteristics and the prognostic significance of del(20q) were investigated in a consecutive series of 213 myeloid malignancies. In the analyses, the cases were divided into three subgroups according to diagnosis or four subgroups according to cytogenetic data. Patients in the myeloproliferative neoplasms subgroup had high WBCs and platelet counts at initial diagnosis. The del(20q) occurred predominantly in older men. Sole del(20q) was observed most often in myelodysplastic syndromes, while del(20q) as a part of complex karyotypes was observed predominantly in acute myeloid leukemia. The most frequent additional abnormalities accompanying del(20q) were -5/del(5q), -7/del(7q) and +8; t(20;21)(q11;q11) and double del(20q) were two rare but recurrent abnormalities secondary to del(20q). In all types of diseases, patients with a sole del(20q) had a favorable prognosis. The presence of any additional abnormality with del(20q) had an unfavorable outcome. Patients with i(20q) had an unfavorable prognosis. Patients with the minor del(20q) clone had a better median survival than those with the major del(20q) clone.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  characteristics; del(20q); myeloid malignancy; prognosis

Mesh:

Year:  2014        PMID: 24699042     DOI: 10.1016/j.cancergen.2014.02.002

Source DB:  PubMed          Journal:  Cancer Genet


  1 in total

1.  Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies.

Authors:  C Cameron Yin; Jie Peng; Yu Li; Rashmi Kanagal-Shamanna; Tariq Muzzafar; Courtney DiNardo; Joseph D Khoury; Shaoying Li; L Jeffrey Medeiros; Sa A Wang; Guilin Tang
Journal:  Mod Pathol       Date:  2015-06-05       Impact factor: 7.842

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.